Abstract
Background: It is unclear whether use of contemporary protease inhibitors pose a similar risk of chronic kidney disease (CKD) as use of older protease inhibitors. Methods: Participants in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study were followed up until the earliest occurrence of CKD, the last visit plus 6 months, or 1 February 2016. Adjusted Poisson regression was used to assess associations between CKD and the use of ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted darunavir (DRV/r). Results: The incidence of CKD (10.0/1000 person-years of follow-up; 95% confidence interval, 9.5-10.4/1000 person-years of follow-up) increased gradually with increasing exposure to ATV/r, but the relation was less clear for DRV/r. After adjustment, only exposure to ATV/r (adjusted incidence rate ratio, 1.4; 95% confidence interval, 1.2-1.6), but not exposure to DRV/r (1.0;. 8-1.3), remained significantly associated with CKD. Conclusion: While DRV/r use was not significantly associated with CKD an increasing incidence with longer ATV/r use was confirmed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1629-1634 |
| Number of pages | 6 |
| Journal | Journal of Infectious Diseases |
| Volume | 220 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 8 2019 |
Fingerprint
Keywords
- adverse drug effect
- atazanavir
- CKD
- darunavir
- HIV
- nephrotoxicity
- protease inhibitors
ASJC Scopus subject areas
- Immunology and Allergy
- Infectious Diseases
Cite this
Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons with Human Immunodeficiency Virus : The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. / Ryom, Lene; Dilling Lundgren, Jens; Reiss, Peter; Kirk, Ole; Law, Matthew; Ross, Mike; Morlat, Phillip; Andreas Fux, Christoph; Fontas, Eric; De Wit, Stephane; D'Arminio Monforte, Antonella; El-Sadr, Wafaa; Phillips, Andrew; Ingrid Hatleberg, Camilla; Sabin, Caroline; Mocroft, Amanda.
In: Journal of Infectious Diseases, Vol. 220, No. 10, 08.10.2019, p. 1629-1634.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons with Human Immunodeficiency Virus
T2 - The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study
AU - Ryom, Lene
AU - Dilling Lundgren, Jens
AU - Reiss, Peter
AU - Kirk, Ole
AU - Law, Matthew
AU - Ross, Mike
AU - Morlat, Phillip
AU - Andreas Fux, Christoph
AU - Fontas, Eric
AU - De Wit, Stephane
AU - D'Arminio Monforte, Antonella
AU - El-Sadr, Wafaa
AU - Phillips, Andrew
AU - Ingrid Hatleberg, Camilla
AU - Sabin, Caroline
AU - Mocroft, Amanda
PY - 2019/10/8
Y1 - 2019/10/8
N2 - Background: It is unclear whether use of contemporary protease inhibitors pose a similar risk of chronic kidney disease (CKD) as use of older protease inhibitors. Methods: Participants in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study were followed up until the earliest occurrence of CKD, the last visit plus 6 months, or 1 February 2016. Adjusted Poisson regression was used to assess associations between CKD and the use of ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted darunavir (DRV/r). Results: The incidence of CKD (10.0/1000 person-years of follow-up; 95% confidence interval, 9.5-10.4/1000 person-years of follow-up) increased gradually with increasing exposure to ATV/r, but the relation was less clear for DRV/r. After adjustment, only exposure to ATV/r (adjusted incidence rate ratio, 1.4; 95% confidence interval, 1.2-1.6), but not exposure to DRV/r (1.0;. 8-1.3), remained significantly associated with CKD. Conclusion: While DRV/r use was not significantly associated with CKD an increasing incidence with longer ATV/r use was confirmed.
AB - Background: It is unclear whether use of contemporary protease inhibitors pose a similar risk of chronic kidney disease (CKD) as use of older protease inhibitors. Methods: Participants in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study were followed up until the earliest occurrence of CKD, the last visit plus 6 months, or 1 February 2016. Adjusted Poisson regression was used to assess associations between CKD and the use of ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted darunavir (DRV/r). Results: The incidence of CKD (10.0/1000 person-years of follow-up; 95% confidence interval, 9.5-10.4/1000 person-years of follow-up) increased gradually with increasing exposure to ATV/r, but the relation was less clear for DRV/r. After adjustment, only exposure to ATV/r (adjusted incidence rate ratio, 1.4; 95% confidence interval, 1.2-1.6), but not exposure to DRV/r (1.0;. 8-1.3), remained significantly associated with CKD. Conclusion: While DRV/r use was not significantly associated with CKD an increasing incidence with longer ATV/r use was confirmed.
KW - adverse drug effect
KW - atazanavir
KW - CKD
KW - darunavir
KW - HIV
KW - nephrotoxicity
KW - protease inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85073088603&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073088603&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiz369
DO - 10.1093/infdis/jiz369
M3 - Article
C2 - 31504669
AN - SCOPUS:85073088603
VL - 220
SP - 1629
EP - 1634
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 10
ER -